RapidAI receives FDA 510(okay) to determine potential pulmonary embolism


Share post:

RapidAI, a well being tech firm that focuses on stroke imaging evaluation, introduced Tuesday it had obtained FDA 510(okay) clearance for its product that goals to determine potential circumstances of central pulmonary embolism and alert suppliers.

The Fast PE Triage & Notification software analyzes CT pulmonary angiogram (CPTA) photographs and alerts care groups when it finds a suspected case, so suppliers can triage sufferers for care.

The corporate, also referred to as iSchemaView, now has six FDA 510(okay) clearances, in response to the FDA’s database. That features its Fast ASPECTS gadget that helps physicians detect mind accidents and determine if a affected person is eligible for a thrombectomy.

“Constructing on our experience in stroke, we’re assured this know-how will assist modernize PE care and meaningfully enhance affected person outcomes,” CEO Karim Karti stated in a press release.

“Our objective is to construct options that deal with the particular challenges related to treating numerous situations, in addition to the communication and workflow points confronted by hospitals globally. From stroke, to aneurysm, to PE, we’re pleased with how a lot RapidAI has grown, and are excited to proceed to redefine the affected person care journey.”


A pulmonary embolism is a blockage in one of many pulmonary arteries within the lungs, most ceaselessly attributable to blood clots that journey from veins within the legs.

The situation may be life-threatening. In keeping with the Mayo Clinic, a couple of third of individuals with undiagnosed and untreated pulmonary embolism do not survive, however fast remedy like medicine or blood clot removing improves outcomes. 


There are a variety of corporations targeted on utilizing synthetic intelligence in imaging. Aidoc lately obtained FDA 510(okay) clearances for flagging and triaging doable circumstances of pneumothorax and one other for discovering potential mind aneurysms. The corporate additionally has an FDA-cleared software for incidental pulmonary embolism.

In February, Viz.ai obtained a 510(okay) for its algorithm that goals to detect mind aneurysms from CT scans. It scored a De Novo in 2018 for its software that analyzes CT outcomes and highlights circumstances that will have skilled a stroke.

Nevertheless, as AI expands in healthcare and life sciences, some research have raised considerations about bias and the necessity for rigorous testing. A research printed in The Lancet Digital Well being earlier this month discovered a deep-learning mannequin could possibly be skilled to foretell self-reported race from imaging outcomes, a outcome the researchers wrote may perpetuate or worsen present well being disparities.

One other Lancet research from April discovered an algorithm used to detect hip fractures outperformed human radiologists, however additional evaluation discovered issues that will make it unsafe to make use of in new environments. The algorithm additionally often made errors a human would take into account simple to interpret.

Supply hyperlink


Please enter your comment!
Please enter your name here


Related articles